The role of the gut microbiota in inflammatory bowel diseases (IBD) has been extensively studied, revealing significant associations between microbial composition and disease pathogenesis. IBD, including Crohn's disease (CD) and ulcerative colitis (UC), is influenced by both genetic and environmental factors, with the gut microbiota playing a crucial role in immune regulation and intestinal homeostasis. Genome-wide association studies have identified genetic loci linked to immune responses against the microbiota, while microbiome profiling has shown characteristic shifts in microbial composition in IBD patients. Recent advances in metagenomic and metabolomic technologies have enhanced understanding of the microbiota's functional roles in IBD, highlighting the importance of microbial diversity and metabolic pathways in disease development. Environmental factors such as diet, age, and lifestyle significantly influence the gut microbiota. Dietary patterns affect microbial composition, with long-term diets altering the ratios of Bacteroides, Prevotella, and Firmicutes. Age-related changes in the microbiome are also evident, with early life characterized by low microbial diversity and stability, and increased instability in the elderly. The microbiota's role in IBD is further supported by genetic studies showing that mutations in genes like NOD2 and ATG16L1 are associated with altered microbial communities and disease susceptibility. Microbial dysbiosis in IBD is marked by reduced biodiversity, decreased Firmicutes, and increased Gammaproteobacteria. Specific taxa, such as Enterobacteriaceae and AIEC strains, are enriched in IBD patients, contributing to inflammation. Fusobacterium species are also implicated in IBD pathogenesis, with their invasive ability correlating with disease severity. Protective microbes, such as Bifidobacterium and Faecalibacterium prausnitzii, help maintain intestinal health by modulating immune responses and producing short-chain fatty acids (SCFAs). Functional studies of the gut microbiota in IBD reveal shifts in metabolic pathways, including reduced butyrate production and increased sulfate-reducing bacteria. These changes are associated with increased oxidative stress and inflammation. Treatments like antibiotics can disrupt the microbiome, leading to dysbiosis and increased infection risk. Probiotics and fecal microbiota transplantation (FMT) are being explored as potential therapies for IBD, with FMT showing promise in treating relapsing C. difficile infections. Future research aims to better understand the complex interactions between the microbiome and host immune system, using advanced sequencing and computational methods. Longitudinal studies and large-scale clinical trials are needed to elucidate the role of the microbiome in IBD and to develop targeted therapies. Standardization of microbiome research protocols and integration of multi-omics approaches will be essential for advancing our understanding and treatment of IBD and related diseases.The role of the gut microbiota in inflammatory bowel diseases (IBD) has been extensively studied, revealing significant associations between microbial composition and disease pathogenesis. IBD, including Crohn's disease (CD) and ulcerative colitis (UC), is influenced by both genetic and environmental factors, with the gut microbiota playing a crucial role in immune regulation and intestinal homeostasis. Genome-wide association studies have identified genetic loci linked to immune responses against the microbiota, while microbiome profiling has shown characteristic shifts in microbial composition in IBD patients. Recent advances in metagenomic and metabolomic technologies have enhanced understanding of the microbiota's functional roles in IBD, highlighting the importance of microbial diversity and metabolic pathways in disease development. Environmental factors such as diet, age, and lifestyle significantly influence the gut microbiota. Dietary patterns affect microbial composition, with long-term diets altering the ratios of Bacteroides, Prevotella, and Firmicutes. Age-related changes in the microbiome are also evident, with early life characterized by low microbial diversity and stability, and increased instability in the elderly. The microbiota's role in IBD is further supported by genetic studies showing that mutations in genes like NOD2 and ATG16L1 are associated with altered microbial communities and disease susceptibility. Microbial dysbiosis in IBD is marked by reduced biodiversity, decreased Firmicutes, and increased Gammaproteobacteria. Specific taxa, such as Enterobacteriaceae and AIEC strains, are enriched in IBD patients, contributing to inflammation. Fusobacterium species are also implicated in IBD pathogenesis, with their invasive ability correlating with disease severity. Protective microbes, such as Bifidobacterium and Faecalibacterium prausnitzii, help maintain intestinal health by modulating immune responses and producing short-chain fatty acids (SCFAs). Functional studies of the gut microbiota in IBD reveal shifts in metabolic pathways, including reduced butyrate production and increased sulfate-reducing bacteria. These changes are associated with increased oxidative stress and inflammation. Treatments like antibiotics can disrupt the microbiome, leading to dysbiosis and increased infection risk. Probiotics and fecal microbiota transplantation (FMT) are being explored as potential therapies for IBD, with FMT showing promise in treating relapsing C. difficile infections. Future research aims to better understand the complex interactions between the microbiome and host immune system, using advanced sequencing and computational methods. Longitudinal studies and large-scale clinical trials are needed to elucidate the role of the microbiome in IBD and to develop targeted therapies. Standardization of microbiome research protocols and integration of multi-omics approaches will be essential for advancing our understanding and treatment of IBD and related diseases.